Mercaptopurine (6-MP)

Catalog No.S1305

Mercaptopurine (6-MP) Chemical Structure

Molecular Weight(MW): 152.18

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Size Price Stock Quantity  
In DMSO USD 100 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells Mon2SpVv[3Srb36gZZN{[Xl? MlHaTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH;uJI12dHSrZIL1[{1z\XOrc4ThcpQhVDF{MUCgcIV2c2WvaXGgZ4VtdHNuIFnDOVA:OC5yMkSg{txO MoTXNVkxPjFyNx?=
MT4 cells MnTPVJJwdGmoZYLheIlwdiCjc4PhfS=> NYm2[Gg1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWFQh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOSEQvF2= M1\1VFE4OjV2Nk[5
human CCRF-CEM cells NIXLOXNRem:uaX\ldoF1cW:wIHHzd4F6 M33uOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN NXXr[IQyOTd{NUS2Olk>
human CCRF-SB cells NF\JVIhRem:uaX\ldoF1cW:wIHHzd4F6 NHLKdmZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuW0JiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN NUHaUo9GOTd{NUS2Olk>
human SK-MEL-28 cells MUjQdo9tcW[ncnH0bY9vKGG|c3H5 M3vGVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1zNTFOwG0> MYSxO|I2PDZ4OR?=
human MCF7 cells Mo[0VJJwdGmoZYLheIlwdiCjc4PhfS=> M4HYcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9N{DPxE1? M4LW[|E4OjV2Nk[5
human HepG2 cells NEL3WIxRem:uaX\ldoF1cW:wIHHzd4F6 MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME24JO69VQ>? MYSxO|I2PDZ4OR?=
human DU145 cells NUWxXpZrWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHH3OFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0zKM7:TR?= NUDWT2NwOTd{NUS2Olk>
mouse J774.A1 cells NIjERoRRem:uaX\ldoF1cW:wIHHzd4F6 NVK2TIREOyCmYYnz NFTiZm5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|QvSTFiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODB|IN88US=> NInMdIcyPjZ2M{C0NC=>
HEK293 cells NF;vd49Rem:uaX\ldoF1cW:wIHHzd4F6 NEfrWI4{KGSjeYO= M3vDcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTGVMOjl|IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiY3;ueoVze2mxbjDhd5NigSxiSVO1NF0xNjByNzFOwG0> NHWy[ooyPjZ2M{C0NC=>
mouse J774 cells NXv1cIFPWHKxbHnm[ZJifGmxbjDhd5NigQ>? MnTCO|IhcA>? NVW5c4x{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVKG2ndHjv[EwhUUN3ME2wMlAxOyEQvF2= MYqxNFc2PzdyOB?=
human PBMC NEjqVphHfW6ldHnvckBie3OjeR?= MUe0JIRigXN? MYjJcohq[mm2aX;uJI9nKFRiY3XscEBucXSxZ3XuMYlv\HWlZXSgZoxie3SxZ3Xu[ZNqeyCrbjDoeY1idiCSQl3DJIFnfGW{IESg[IF6eyxiSVO1NF0xNjF2OUWg{txO MVGxPFQ3PzByNx?=
HeLa cells MnzwR5l1d3SxeHnjbZR6KGG|c3H5 MXK0PEBp NIL3cWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG2IHzh[{BxcGG|ZTDv[kBoem:5dHigZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lkmg{txO MUCxPVcyOTl6Nx?=
A549 cells MYHDfZRwfG:6aXPpeJkh[XO|YYm= MWe0PEBp M4KwTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XRibHHnJJBp[XOnIH;mJIdzd3e2aDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTR5IN88US=> NYjDNFNzOTl5MUG5PFc>
MCF7 cells MX7DfZRwfG:6aXPpeJkh[XO|YYm= MVS0PEBp MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF1KGyjZzDwbIF{\SCxZjDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjRizszN MYOxPVcyOTl6Nx?=
MT4 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= NFzjTYw6PiCq MlrnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIlv\mWldHXkJJdqfGhiSGTMWk0yKGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NE4yKM7:TR?= NUj3WFk1OjF5NEGxN|A>
CCRF-CEM cells NYLzRotHWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUjKUnlZQTZiaB?= NHrRUFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuS0WPIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NUDPxE1? MofTNlE4PDFzM{C=
WIL2-NS cells NYmyOG9bWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{jDTlk3KGh? Mle2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCZSVyyMW5UKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MzFOwG0> MoO2NlE4PDFzM{C=
CCRF-SB cells NGLVNnRRem:uaX\ldoF1cW:wIHHzd4F6 NGKzSHM6PiCq NWP1Xow{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDR3JHNVOEIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NU4yKM7:TR?= NV25PW82OjF5NEGxN|A>
human DU145 cells MWjQdo9tcW[ncnH0bY9vKGG|c3H5 NWXxbGRWQTZiaB?= NFrw[WRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;MjFOwG0> NGTvbmQzOTd2MUGzNC=>
human HepG2 cells M3vhRXBzd2yrZnXyZZRqd25iYYPzZZk> NFuyT|Q6PiCq MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:QCEQvF2= NIi3TngzOTd2MUGzNC=>
MCF7 cells MVzQdo9tcW[ncnH0bY9vKGG|c3H5 NHvmfIc6PiCq M1rNUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDDR|UxRTNwMjFOwG0> NIDKNW8zOTd2MUGzNC=>
SK-MEL-28 cells MVHQdo9tcW[ncnH0bY9vKGG|c3H5 MoPzPVYhcA>? MmXmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuOjhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2xOUDPxE1? M1TTc|IyPzRzMUOw
MCF7 cells MX;DfZRwfG:6aXPpeJkh[XO|YYm= M1rqUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMtKEmFNUC9Nk44QSEQvF2= MkT3NlM1OTF7MUW=
mouse S49 cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= NVzGfJJPPzJiaB?= MkDrR5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKG2xdYPlJHM1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCHQ{WwQVgh|ryP NWTEbGVxOjJzNkW4
Colo-357 cells MYfDfZRwfG:6aXPpeJkh[XO|YYm= M4HvbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNwdG9vM{W3JINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTZwMUKg{txO M{LQelIxQTNyMUKz
Aspc-1 cells NGjEZWJEgXSxdH;4bYNqfHliYYPzZZk> MnT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRZNx[y1zIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVIvPDVizszN MlO3NlA6OzBzMkO=
A549 cells MlHzR5l1d3SxeHnjbZR6KGG|c3H5 NX73UppbPDhiaB?= M{LXbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20O{DPxE1? MVOyNlcxPTByMR?=
MCF7 cells Mnq1R5l1d3SxeHnjbZR6KGG|c3H5 NHLjR241QCCq M3XGcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlQh|ryP NIT3NJEzOjdyNUCwNS=>
Patu-02 cells MmPjR5l1d3SxeHnjbZR6KGG|c3H5 NG\zbW9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR[XS3LUCyJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTlwNkmg{txO NYDI[mY4OjB7M{CxNlM>
Patu-T cells M2nwZWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4f0bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBifHVvVDDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF01NjB7IN88US=> MXyyNFk{ODF{Mx?=
Patu-S cells MkHaR5l1d3SxeHnjbZR6KGG|c3H5 MnLWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIF1fS2VIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVEyNjB5IN88US=> MV[yNFk{ODF{Mx?=
T3M4 cells M2\t[2N6fG:2b4jpZ4l1gSCjc4PhfS=> MmjwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFNOPCClZXzsd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whUUN3ME2yMlY{KM7:TR?= M1nScVIxQTNyMUKz
human PANC1 cells NGfKPHlEgXSxdH;4bYNqfHliYYPzZZk> NIH3OVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSU6FMTDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF03NjN7IN88US=> MWeyNFk{ODF{Mx?=
human DAN-G cells MUDDfZRwfG:6aXPpeJkh[XO|YYm= MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDERW4uTyClZXzsd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whUUN3ME20MlA3KM7:TR?= NYXp[2xFOjB7M{CxNlM>
HeLa cells NEXMeY5EgXSxdH;4bYNqfHliYYPzZZk> M4LG[|Q5KGh? M{DsN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlkh|ryP MWiyNlcxPTByMR?=
WEHI164 cells NHrBeWVRem:uaX\ldoF1cW:wIHHzd4F6 MY[zJIRigXN? MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFeHSFmxOlQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBkd264ZYLzbY9vKGG|c3H5MEBKSzVyPUCuNFE2KM7:TR?= MV:xOlY1OzB2MB?=
WIL-2NS cells NV75Z5YxWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLTD2yUnMh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMh|ryP MWSxO|I2PDZ4OR?=
WEHI164 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 MVm3NkBp MkTnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCZRVjJNVY1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVKG2ndHjv[EwhUUN3ME2wMlAyPyEQvF2= MV2xNFc2PzdyOB?=

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (197.13 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00514982 Withdrawn Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 7, 2007 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT02578511 Not yet recruiting Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma in Complete Remission|Mixed Phenotype Acute Leukemia in Complete Remission Ehab L Atallah|Medical College of Wisconsin January 2017 Phase 1
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02828358 Not yet recruiting Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia National Cancer Institute (NCI) December 2016 --
NCT02877303 Recruiting Leukemia|Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center|Amgen November 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID